



## ASX ANNOUNCEMENT

### CEO & Managing Director fixed term contract converted to permanent position

---

**2 July 2025** – Cann Group Limited (“**Cann**” or the “**Company**”) today announced that it has executed a permanent employment agreement with Ms Jenni Pilcher, in the role of CEO & Managing Director (**New Employment Contract**).

This follows the Company’s previous announcement, made on the 15 July 2024, relating to the appointment of Ms Jenni Pilcher as CEO & Managing Director, on a fixed-term contract which ended 1 July 2025 (**Previous Employment Contract**).

With the exception of the contract term (now a permanent position requiring four (4) months’ notice for termination), the remaining key terms of the New Employment Contract are consistent with the key terms of the Previous Employment Contract, as described in the 15 July 2024 announcement.

Chairman, Doug Rathbone, commented: “The Board has been highly impressed with Jenni’s performance in her recent tenure as CEO and Managing Director. We are pleased that she has accepted the position on a permanent basis, a decision we believe strongly aligns with the best interests of the Company”.

**Authorised for release by the Board of Directors, Cann Group Limited.**

**For all other information please contact:**

Jenni Pilcher  
CEO & Managing Director  
Cann Group Limited  
+61 3 9095 7088  
[contact@canngrouponlimited.com](mailto:contact@canngrouponlimited.com)

Steven Notaro  
Company Secretary  
Cann Group Limited  
+61 3 9095 7088  
[contact@canngrouponlimited.com](mailto:contact@canngrouponlimited.com)

**About Cann Group**

Cann Group Limited (ABN 25 603 949 739) is enhancing patients’ lives by developing, producing, and supplying innovative cannabis medicines. The Company has research facilities and corporate headquarters in Melbourne and operates a state-of-the-art large-scale cultivation and GMP manufacturing facility near Mildura, Victoria. Cann Group supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. Cann Group also owns Satipharm and its patent-protected capsule technology.

**Learn more at:** [www.canngrouponlimited.com](http://www.canngrouponlimited.com) | [www.satipharm.com](http://www.satipharm.com)